The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia:: is achievement of molecular remission worthwhile?

被引：27

作者：

Dreger, P

Ritgen, M

Böttcher, S

Schmitz, N

Kneba, M

机构：

[1] Univ Heidelberg, Dept Med 5, D-69120 Heidelberg, Germany

[2] Univ Schleswig Holstein, Dept Med 2, Kiel, Germany

[3] Allgemein Krankenhaus St Georg, Dept Hematol, Hamburg, Germany

来源：

LEUKEMIA | 2005年 / 19卷 / 07期

关键词：

D O I：

10.1038/sj.leu.2403800

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1135 / 1138

页数：4

共 22 条

[1] Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation [J].

Böttcher, S ;

Ritgen, M ;

Pott, C ;

Brüggemann, M ;

Raff, T ;

Stilgenbauer, S ;

Döhner, H ;

Dreger, P ;

Kneba, M .

LEUKEMIA, 2004, 18 (10) :1637-1645

[2] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].

Byrd, JC ;

Peterson, BL ;

Morrison, VA ;

Park, K ;

Jacobson, R ;

Hoke, E ;

Vardiman, JW ;

Rai, K ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2003, 101 (01) :6-14

[3]

Byrd John C, 2004, Hematology Am Soc Hematol Educ Program, P163

[4] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].

Cheson, BD ;

Bennett, JM ;

Grever, M ;

Kay, N ;

Keating, MJ ;

OBrien, S ;

Rai, KR .

BLOOD, 1996, 87 (12) :4990-4997

[5] Early stem cell transplantation for chronic lymphocytic leukaemia:: a chance for cure? [J].

Dreger, P ;

von Neuhoff, N ;

Kuse, R ;

Sonnen, R ;

Glass, B ;

Uharek, L ;

Schoch, R ;

Löffler, H ;

Schmitz, N .

BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2291-2297

[6] Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia [J].

Dreger, P ;

Montserrat, E .

LEUKEMIA, 2002, 16 (06) :985-992

[7] Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia [J].

Esteve, J ;

Villamor, N ;

Colomer, D ;

Montserrat, E .

BLOOD, 2002, 99 (05) :1873-1874

[8] Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status [J].

Esteve, J ;

Villamor, N ;

Colomer, D ;

Cervantes, F ;

Campo, E ;

Carreras, E ;

Montserrat, E .

LEUKEMIA, 2001, 15 (03) :445-451

[9]

KEATING MJ, 2003, J CLIN ONCOL

[10] Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients [J].

Leporrier, M ;

Chevret, S ;

Cazin, B ;

Boudjerra, N ;

Feugier, P ;

Desablens, B ;

Rapp, MJ ;

Jaubert, J ;

Autrand, C ;

Divine, M ;

Dreyfus, B ;

Maloum, K ;

Travade, P ;

Dighiero, G ;

Binet, JL ;

Chastang, C .

BLOOD, 2001, 98 (08) :2319-2325

← 1 2 3 →